Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study

Dahab, Mison; Charalambous, Salome; Karstaedt, Alan S.; Fielding, Katherine L.; Hamilton, Robin; La Grange, Lettie; Churchyard, Gavin J.; Grant, Alison D.
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p430
Academic Journal
Background: Many national antiretroviral therapy (ART) programmes encourage providers to identify and address baseline factors associated with poor treatment outcomes, including modifiable adherence-related behaviours, before initiating ART. However, evidence on such predictors is scarce, and providers judgement may often be inaccurate. To help address this evidence gap, this observational cohort study examined baseline factors potentially predictive of poor treatment outcomes in two ART programmes in South Africa, with a particular focus on determinants of adherence. Methods: Treatment-naïve patients starting ART were enrolled from a community and a workplace ART programme. Potential baseline predictors associated with poor treatment outcomes (defined as viral load > 400 copies/ml or having discontinued treatment by six months) were assessed using logistic regression. Exposure variables were organised for regression analysis using a hierarchical framework. Results: 38/227 (17%) of participants in the community had poor treatment outcomes compared to 47/117 (40%) in the workplace. In the community, predictors of worse outcomes included: drinking more than 20 units of alcohol per week, having no prior experience of chronic medications, and consulting a traditional healer in the past year (adjusted odds ratio [aOR] 15.36, 95% CI 3.22-73.27; aOR 2.30, 95%CI 1.00-5.30; aOR 2.27, 95% CI 1.00-5.19 respectively). Being male and knowing someone on ART were associated with better outcomes (aOR 0.25, 95%CI 0.09-0.74; aOR 0.44, 95%CI 0.19-1.01 respectively). In the workplace, predictors of poor treatment outcomes included being uncertain about the health effects of ART and a traditional healer's ability to treat HIV (aOR 7.53, 95%CI 2.02-27.98; aOR 4.40, 95%CI 1.41-13.75 respectively). Longer pre-ART waiting time (2-12 weeks compared to <2 weeks) predicted better treatment outcomes (aOR 0.13, 95% CI 0.03-0.56). Conclusion: Baseline predictors of poor treatment outcomes were largely unique to each programme, likely reflecting different populations and pathways to HIV care. In the workplace, active promotion of HIV testing may have extended ART to individuals who, without provider initiation, would not have spontaneously sought care. As provider-initiated testing makes ART available to individuals less motivated to seek care, patients may need additional adherence support, especially addressing uncertainty about the health benefits of ART.


Related Articles

  • Didanosine/nevirapine/zidovudine.  // Reactions Weekly;8/11/2007, Issue 1164, p13 

    The article describes the case of a woman who developed nodular regenerative hyperplasia during treatment with highly active antiretroviral therapy (HAART), including didanosine, nevirapine and zidovudine, for HIV infection. The patient, who had a history of liver fracture and had been diagnosed...

  • Benefit or Toxicity from Neurologically Targeted Antiretroviral Therapy? Brew, Bruce J. // Clinical Infectious Diseases;3/15/2010, Vol. 50 Issue 6, p930 

    In this article, the author discusses the treatment of HIV-related neurocognitive disorders. The author states that milder forms of HIV-related neurocognitive diseases are more usual than HIV-related dementia and have not altered with using highly active antiretroviral therapy (HAART). The...

  • Review of antiretroviral agents for the treatment of HIV infection. Stanic, Anela; Grana, Julie C. // Formulary;Feb2009, Vol. 44 Issue 2, p47 

    Research into the treatment of HIV infection has resulted in the development of 5 antiretroviral (ARV) drug classes: entry inhibitors, including fusion inhibitors and chemokine coreceptor (CCR) inhibitors; nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse...

  • Human Immunodeficiency Virus Interactions with CD8+ T Lymphocytes. Saksena, Nitin K.; Jing Qin Wu; Potter, Simon J.; Wilkinson, John; Bin Wang // Current HIV Research;Jan2008, Vol. 6 Issue 1, p1 

    Human immunodeficiency virus (HIV)-specific CD8+ T cells can mediate anti-HIV activity by both cytolytic (cytotoxic T lymphocyte or CTL) and non-cytolytic mechanisms (antiviral) and play a crucial role in HIV pathogenesis. Both mechanisms actively contribute to the control of HIV in vivo. The...

  • Financial situation of people living with HIV in Europe. Schrooten, W.; Dreezen, C.; Borleffs, J.; Dijkgraaf, M.; Borchert, M.; de Graeve, D.; Hemmer, R.; Fleerackers, Y.; Colebunders, R. // International Journal of STD & AIDS;Oct2002, Vol. 13 Issue 10, p698 

    The objective was to investigate the financial situation of people living with HIV in Europe. Two surveys using an anonymous questionnaire were organized in Europe among people living with HIV, the first in 1996-97 and the second in 1998-99. One thousand one hundred and sixty-one people from the...

  • Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. McCarthy, K.; Chersich, M. F.; Vearey, J.; Meyer-Rath, G.; Jaffer, A.; Simpwalo, S.; Venter, W. D. F. // International Journal of STD & AIDS;Dec2009, Vol. 20 Issue 12, p858 

    Summary: Foreigners, including displaced persons, often have limited health-care access, especially to HIV services. Outcomes of antiretroviral therapy (ART) in South Africans and foreigners were compared at a Johannesburg non-governmental clinic. Records were reviewed of 1297 adults enrolled...

  • Loss of correlation between HIV viral load and CD4 + T-cell counts in HIV/HTLV-1 co-infection in treatment naïve Mozambican patients. Bhatt, N. B.; Gudo, E. S.; Semá, C.; Bila, D.; Di Mattel, P.; Augusto, O.; Garsia, R.; Jani, I. V. // International Journal of STD & AIDS;Dec2009, Vol. 20 Issue 12, p863 

    Summary: Seven hundred and four HIV-1 /2-positive, antiretroviral therapy (ART) naïve patients were screened for HTLV-1 infection. Antibodies to HTLV-1 were found in 32/704 (4.5%) of the patients. Each co-infected individual was matched with two HIV mono-infected patients according to World...

  • PRO 140 - A Novel CCR5 Co-Receptor Inhibitor. Khatib, Nadia; Das, Satyajit // Recent Patents on Anti-Infective Drug Discovery;Jan2010, Vol. 5 Issue 1, p18 

    Despite an increase in the variety of anti-retroviral agents in the market, there remains a need for novel agents to treat HIV 1 infected individuals, in order to overcome existing problems with adherence, toxicities, drug interactions and viral resistance. In this article, we will describe Pro...

  • Management of HIV-1 infection in adults. Nguyen, Thien Huong // Baylor University Medical Center Proceedings;Jan2009, Vol. 22 Issue 1, p62 

    The article presents information related to the management of human immunodeficiency virus (HIV) infection. According to the Joint United Nations Programme on HIV/AIDS 2008 report on the global AIDS epidemic, 30.8 million adults and 2 million children suffered HIV at the end of 2007. Due to the...

  • HIV-2 Infection: Where Are We Today? Ingole, Nayana A.; Sarkate, Purva P.; Paranjpe, Supriya M.; Shinde, Sameer D.; Lall, Sujata S.; Mehta, Preeti R. // Journal of Global Infectious Diseases; 

    Context: The choice of antiretroviral therapy for HIV-2 differs from that for HIV-1, underscoring the importance of differentiating between the two. Aims: The current study was planned to find out the prevalence of HIV-2 infection at our center and to find out the utility of the current...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics